Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.

THE very first known successful operation for removal of a pheochromocytoma was performed by Cesar Roux in February 1926 in Lausanne, Switzerland (1). C. H. Mayo performed the first successful removal of a pheochromocytoma in North America in October of the same year (2). Since these first successful operations, considerable progress has been made in the diagnosis and treatment of pheochromocytoma. The availability of sensitive and specific immunoassay procedures, the development of simplified diagnostic testing, and the introduction of sensitive imaging techniques have enhanced the clinician's ability to make the diagnosis with greater certainty. In addition, a better understanding of catecholamine action and the pathophysiology of pheochromocytoma and an appreciation of the wide range of clinical manifestations associated with it have led not only to earlier recognition of the disease but also to a more rational approach to its diagnosis and management. Nevertheless, there are still uncertainties regard...

[1]  M. P. Canale,et al.  Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. , 1994, The Journal of clinical endocrinology and metabolism.

[2]  H. Neumann,et al.  Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. , 1993, The New England journal of medicine.

[3]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[4]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[5]  G. Smythe,et al.  Laboratory Diagnosis of Phaeochromocytoma: Which Analytes Should We Measure? , 1993, Annals of clinical biochemistry.

[6]  J. O'fallon,et al.  Prognostic profile for patients with pheochromocytoma derived from clinical and pathological factors and DNA ploidy pattern , 1992, Journal of surgical oncology.

[7]  L. Quint,et al.  Integrated imaging of adrenal disease. , 1992, Radiology.

[8]  J. O'fallon,et al.  The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma , 1992, Cancer.

[9]  R. J. Sjoberg,et al.  The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. , 1992, Archives of internal medicine.

[10]  D. Kuhl,et al.  PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M. Tristam,et al.  Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. , 1991, Journal of nuclear biology and medicine.

[12]  K. Zasadny,et al.  Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. , 1991, Journal of nuclear biology and medicine.

[13]  M. Friedlander,et al.  Prognostic significance of nuclear DNA content in phaeochromocytoma. , 1991, The Australian and New Zealand journal of surgery.

[14]  D. Goldstein,et al.  Glucagon and Clonidine Testing in the Diagnosis of Pheochromocytoma , 1991, Hypertension.

[15]  M. Krempf,et al.  Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. , 1991, The Journal of clinical endocrinology and metabolism.

[16]  A. V. D. van der Mey,et al.  MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas. , 1991, Radiographics : a review publication of the Radiological Society of North America, Inc.

[17]  R. Schimke.  Multiple endocrine neoplasia: how many syndromes? , 1990, American journal of medical genetics.

[18]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[19]  E. Krenning,et al.  Somatostatin-receptor imaging in the localization of endocrine tumors. , 1990, The New England journal of medicine.

[20]  A. Boutros,et al.  Perioperative management of 63 patients with pheochromocytoma. , 1990, Cleveland Clinic journal of medicine.

[21]  F. Fouad-Tarazi,et al.  A Reevaluation of the Hemodynamics of Pheochromocytoma , 1990, Hypertension.

[22]  S. Oishi,et al.  Urinary normetanephrine and metanephrine measured by radioimmunoassay for the diagnosis of pheochromocytoma: utility of 24-hour and random 1-hour urine determinations. , 1988, The Journal of clinical endocrinology and metabolism.

[23]  E. Gelmann,et al.  Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. , 1988, Annals of internal medicine.

[24]  A H Tashjian,et al.  The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. , 1988, The New England journal of medicine.

[25]  L. Quint,et al.  Imaging of the adrenal glands. , 1988, Investigative radiology.

[26]  J. Norton,et al.  Differentiation of adrenal masses by magnetic resonance imaging. , 1987, Surgery.

[27]  H. Vasen,et al.  Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration. A study of 15 kindreds in The Netherlands. , 1987, The American journal of medicine.

[28]  G. Tsujimoto,et al.  Desensitization of postjunctional alpha 1- and alpha 2-adrenergic receptor-mediated vasopressor responses in rat harboring pheochromocytoma. , 1987, Circulation research.

[29]  M. Maze,et al.  Role of the sympathetic nervous system in the maintenance of hypertension in rats harboring pheochromocytoma. , 1987, The Journal of pharmacology and experimental therapeutics.

[30]  P. Coates,et al.  A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor. , 1987, The Journal of endocrinology.

[31]  K. Svärdsudd,et al.  Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. , 2009, Acta medica Scandinavica.

[32]  G. S. Kidd,et al.  Lactic acidosis in pheochromocytoma. , 1986, Annals of internal medicine.

[33]  P. D. de Leeuw,et al.  Noncardiogenic pulmonary edema as the sole manifestation of pheochromocytoma. , 1986, Hypertension.

[34]  A. Grossman,et al.  NALOXONE PROVOKES CATECHOLAMINE RELEASE IN PHAEOCHROMOCYTOMAS AND PARAGANGLIOMAS , 1986, Clinical endocrinology.

[35]  A. Lee,et al.  An adrenocorticotropic hormone-producing pheochromocytoma: diagnostic and immunohistochemical studies. , 1986, The Journal of urology.

[36]  N. K. Krane.  Clinically unsuspected pheochromocytomas. Experience at Henry Ford Hospital and a review of the literature. , 1986, Archives of internal medicine.

[37]  D. Perry-Keene,et al.  Phaeochromocytoma in Queensland--1970-83. , 1985, The Australian and New Zealand journal of surgery.

[38]  E. Bravo,et al.  Current concepts. Pheochromocytoma: diagnosis, localization and management. , 1984, The New England journal of medicine.

[39]  D. White,et al.  Labetalol and phaeochromocytoma. , 1984, British journal of anaesthesia.

[40]  D. O'Connor,et al.  Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. , 1984, The New England journal of medicine.

[41]  C. Cohen,et al.  Phaeochromocytoma and acute cardiovascular death (with special reference to myocardial infarction). , 1984, Postgraduate medical journal.

[42]  F. Saegesser.  César Roux (1857-1934) et son époque. , 1984 .

[43]  V. Dzau,et al.  Symptomatic hypotension following the clonidine suppression test for pheochromocytoma. , 1983, Archives of internal medicine.

[44]  J. Laragh,et al.  Pheochromocytoma and prazosin. , 1983, Annals of internal medicine.

[45]  B. Lorell,et al.  PHAEOCHROMOCYTOMA AND HYPERTROPHIC CARDIOMYOPATHY: APPARENT SUPPRESSION OF SYMPTOMS AND NORADRENALINE SECRETION BY CALCIUM-CHANNEL BLOCKADE , 1983, The Lancet.

[46]  E. Espiner,et al.  Hypoglycaemia following removal of phaeochromocytoma: case report and review of the literature , 1982, Postgraduate medical journal.

[47]  S. Textor,et al.  Blood Pressure Regulation in Pheochromocytoma , 1982, Hypertension.

[48]  V. M. Riccardi,et al.  Von Recklinghausen neurofibromatosis. , 1981, The New England journal of medicine.

[49]  B. Vandeleene,et al.  Labetalol and Pheochromocytoma , 1982 .

[50]  R W Gifford,et al.  Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. , 1981, The New England journal of medicine.

[51]  G. Jennings,et al.  Effect of propranolol on noradrenaline kinetics in patients with essential hypertension. , 1981, British journal of clinical pharmacology.

[52]  J. Chiasson,et al.  Inhibitory effect of epinephrine on insulin-stimulated glucose uptake by rat skeletal muscle. , 1981, The Journal of clinical investigation.

[53]  W. Beierwaltes,et al.  Scintigraphic localization of pheochromocytoma. , 1981, The New England journal of medicine.

[54]  S. Sheps,et al.  Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. , 1981, Mayo Clinic proceedings.

[55]  M. Achong,et al.  Pheochromocytoma unmasked by desipramine therapy. , 1981, Annals of internal medicine.

[56]  A. Simon,et al.  Haemodynamics in patients with phaeochromocytoma. , 1980, Clinical science.

[57]  R W Gifford,et al.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. , 1979, The New England journal of medicine.

[58]  M. Hamaji.  Pancreatic α- and β-Cell Function in Pheochromocytoma , 1979 .

[59]  A. Edis,et al.  Pheochromocytoma associated with hypercalcemia and ectopic secretion of calcitonin. , 1979, Annals of internal medicine.

[60]  V. Livolsi,et al.  Ectopic ACTH syndrome due to pheochromocytoma: case report and review of the literature. , 1979, The Yale journal of biology and medicine.

[61]  N. Morgunov,et al.  Tubular secretion and metabolism of dopamine, norepinephrine, methoxytyramine and normetanephrine by the rat kidney. , 1979, The Journal of pharmacology and experimental therapeutics.

[62]  J. Haaga,et al.  Localization of Pheochromocytoma by Computed Tomography , 1978 .

[63]  Zimmerman Bg.  Actions of angiotensin on adrenergic nerve endings. , 1978 .

[64]  W. Louis,et al.  Abnormalities in enzymes involved in catecholamine synthesis and catabolism in phaeochromocytoma. , 1977, Clinical science and molecular medicine.

[65]  E. Agabiti-Rosei,et al.  HYPERTENSIVE CRISIS IN PATIENTS WITH PHAEOCHROMOCYTOMA GIVEN METOCLOPRAMIDE , 1977, The Lancet.

[66]  T. Cheng,et al.  Striking electrocardiographic changes associated with pheochromocytoma. Masquerading as ischemic heart disease. , 1976, Chest.

[67]  S. Sheps,et al.  Current Management of Pheochromocytoma , 1974, Annals of surgery.

[68]  J. Raker,et al.  Pheochromocytoma with predominant epinephrine secretion. , 1969, The American journal of medicine.

[69]  E. Frohlich,et al.  Tilt Test for Investigating a Neural Component in Hypertension: Its Correlation with Clinical Characteristics , 1967, Circulation.

[70]  A. Lawrence.  Glucagon provocative test for pheochromocytoma. , 1967, Annals of internal medicine.

[71]  E. Rooke,et al.  The neurologist's experience with pheochromocytoma. A review of 100 cases. , 1966, JAMA.

[72]  H. Burchell,et al.  Focal myocarditis associated with pheochromocytoma. , 1966, The New England journal of medicine.

[73]  A. Sjoerdsma,et al.  TURNOVER AND METABOLISM OF CATECHOLAMINES IN PATIENTS WITH PHEOCHROMOCYTOMA. , 1964, The Journal of clinical investigation.

[74]  M. Melicow,et al.  Pheochromocytoma in children , 1963 .

[75]  J. Sipple.  The association of pheochromocytoma with carcinoma of the thyroid gland , 1961 .